Faculty

Institution

Unit

Venue

Donald A. Berry

The University of Texas MD Anderson Cancer Center

Affiliations

The University of Texas MD Anderson Cancer Center

Donald A. Berry is a High Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on adaptive Bayesian clinical trial design, with specific applications to oncology, including glioblastoma platform trials, breast cancer treatment, and drug combination strategies. He has led the GBM AGILE phase II/III Bayesian randomized platform trial evaluating regorafenib in newly diagnosed and recurrent glioblastoma, and contributed to the I-SPY 2 neoadjuvant trial investigating immune checkpoint inhibitor biomarkers. His recent work includes analyses of US breast cancer mortality trends and statistical innovations for multiple-therapy factorial designs. He has published in JAMA, Journal of Clinical Oncology, and Neuro-Oncology, and is recognized for advancing adaptive trial methodology in cancer research.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Donald A. Berry

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology breast cancer medicine clinical trials cancer care cancer research radiation oncology cancer treatment pharmacology clinical research breast oncology medicinal research health sciences cancer biology cancer management pharmacotherapy bayesian analysis experimental medicine tumor biology drug trials survival analysis randomized controlled trials statistical methodology surgical oncology anti-cancer agents oncogenes leukemia applied statistics tumor targeting molecular cancer bayesian inference cancer screening cancer genetics cellular therapy cancer cells cancer imaging applied pharmacology cancer risk bayesian statistics cancer genomics jama oncology therapeutic efficacy gynecologic oncology metastatic breast cancer drug targeting cancer prevention prognosis clinical radiation oncology hematological malignancies meta-analysis neoadjuvant chemotherapy optimal experimental design medical decision analysis exploration v exploitation epidemiology of cancer radiation therapy medical statistics clinical evidence novel therapies neoadjuvant therapy standard neoadjuvant therapy medical genetics clinical mycology drug development node-positive breast cancer pathologic complete response adaptive clinical trials high-risk breast cancer high-dose chemotherapy acute myeloid leukemia early breast cancer adjuvant therapy early-stage breast cancer breast cancer mortality older women flecainide acetate

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: Gbm Agile Phase II/III Bayesian Randomized Platform Trial. Journal of Clinical Oncology (2026)

clinical radiation oncologyneurologymetronomic therapyradiation oncologycancer caregliomasmetronomic chemotherapyrecurrent glioblastomabrain tumor researchcancer discoverymedicinecancer treatmentclinical trialsoncologyneuro-oncology

Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research. Journal of Clinical Medicine (2025)

bayesian statisticsbiostatisticsstatistical methodologyrandomized controlled trialsmedical statisticsdrug trialsbayesian inferencemedicineclinical researchstatistical inferenceclinical trialsbayesian analysisstatistics

Statistical Innovations in Clinical Trial Design With a Focus on Drug Combinations, Factorials, and Other Multiple Therapy Issues. The Journal of Prevention of Alzheimer s Disease (2025)

statistical hypothesis testbiostatisticsrandomized controlled trialsindividualized medicineapplied pharmacologyclinical trial designdrug trialstreatment planningstatistical innovationsmedicineexperimental medicinedrug combinationspharmacotherapyclinical trials

Tip-10. Update on Gbm Agile: A Global, Phase 2/3 Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma. Neuro-Oncology (2025)

neurologyradiation oncologycancer caretreatment plan evaluationgliomasrecurrent glioblastomabrain tumor researchmolecular canceradaptive platform trialcancer discoverygbm agilecancer managementcancer treatmenttumor heterogeneityclinical trialsoncologyneuro-oncology

638P Final Results of Impact 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center. Annals of Oncology (2024)

A.M. TsimberidouS. FuD.S. HongS.A. Piha-PaulA. NaingJ. RodonT.A. YapD. KarpE.E. DumbravaJ.V. HeymachJ.A. AjaniC. CartwrightJ. BecKC. AndersenM. KahleD. ViningJ.S. RossC. ChaoD.A. BerryF. Meric-Bernstam

targeted agentsmolecular profilingcancer researchmetastatic canceroncology

Analysis of Breast Cancer Mortality in the Us—1975 to 2019. JAMA (2024)

Jennifer L. Caswell-JinLiyang P. SunDiego MunozYing LuYisheng LiHui HuangJohn M. HamptonJuhee SongJinani JayasekeraClyde SchechterOguzhan AlagozNatasha K. StoutAmy Trentham-DietzSandra J. LeeXuelin HuangJeanne S. MandelblattDonald A. BerryAllison W. KurianSylvia K. Plevritis

mortalitypublic healthepidemiologybreast cancer mortalitystatisticspopulation healthsurvival analysisbreast cancer

Annual Versus Biennial Mammographic Screening. Journal of Clinical Oncology (2024)

radiologycancer imagingcancer screeningdiagnosis

Ltbk-02. Evaluation of Paxalisib in Gbm Agile Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma. Neuro-Oncology (2024)

Ingo K MellinghoffTimothy CloughesyBrian AlexanderDonald A BerryMeredith BuxtonWebster CaveneeHoward ColmanJohn de GrootBenjamin M EllingsonGary B GordonAndrew B LassmanMichael LimMustafa KhasrawJames PerryErik P SulmanMichael WellerPatrick WenW K Alfred YungNicholas BerryTodd GravesMichelle DetryE M Viktoria HyddmarkAdam JohnssonHeather KlingAnna McGlothlinAshley PowellSarah UntchElisa AquilantiNicholas BlondinBrian BoulmayMacarena de la FuenteJan DrappatzJustin JordanThomas J KaleyMina LobbousTom MikkelsenHerbert NewtonScott OwenKatherine PetersDavid SchiffWendy ShermanShiao-Pei WeathersMichael YoussefJohn FriendEudocia Lee

brain lesionregistration platform trialgliomasneurosciencevascular biologyneurosurgeryearly diagnosismedicinal researchmolecular diagnosticsfield trialneuroimagingurologycancer managementclinical trialsneurologyclinical neurologyrecurrent glioblastomabrain tumor researchoncologyneuro-oncology

Multi-Platform Biomarkers of Response to an Immune Checkpoint Inhibitor in the Neoadjuvant I-Spy 2 Trial for Early-Stage Breast Cancer. Cell Reports Medicine (2024)

Michael J. CampbellDenise M. WolfChristina YauLamorna Brown-SwigartJulie WulfkuhleIsela R. GallagherZelos ZhuJennifer BolenScott VandenbergClifford HoytHidetoshi MoriAlexander BorowskyLaura SitJane PerlmutterSmita M. AsareRita NandaMinetta C. LiuDouglas YeeAngela M. DeMicheleNola M. HyltonLajos PusztaiDonald A. BerryGillian L. HirstEmanuel F. PetricoinLaura van’t VeerLaura Esserman

early-stage breast cancercancer biologymulti-platform biomarkerscancer researchmedicinebiomarkersimmune checkpoint inhibitorsbreast cancer

Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of Checkmate 627, an Adaptive Basket Design Clinical Trial. JCO oncology advances. (2024)

metastasisradiation oncologyrare cancerscancer immunotherapymetastatic malignanciesimmune checkpoint inhibitorsjama oncologycancer managementurologycancer treatmentcancer careoncologycheckmate 627

1
2
3
4
5
41
10 / page

Donald A. Berry

The University of Texas MD Anderson Cancer Center

Affiliations

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Donald A. Berry

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: Gbm Agile Phase II/III Bayesian Randomized Platform Trial. Journal of Clinical Oncology (2026)

Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research. Journal of Clinical Medicine (2025)

Statistical Innovations in Clinical Trial Design With a Focus on Drug Combinations, Factorials, and Other Multiple Therapy Issues. The Journal of Prevention of Alzheimer s Disease (2025)

Tip-10. Update on Gbm Agile: A Global, Phase 2/3 Adaptive Platform Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma. Neuro-Oncology (2025)

638P Final Results of Impact 2, a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center. Annals of Oncology (2024)

targeted agentsmolecular profilingcancer researchmetastatic canceroncology

Analysis of Breast Cancer Mortality in the Us—1975 to 2019. JAMA (2024)

mortalitypublic healthepidemiologybreast cancer mortalitystatisticspopulation healthsurvival analysisbreast cancer

Annual Versus Biennial Mammographic Screening. Journal of Clinical Oncology (2024)

radiologycancer imagingcancer screeningdiagnosis

Ltbk-02. Evaluation of Paxalisib in Gbm Agile Phase 3 Registration Platform Trial for Newly Diagnosed and Recurrent Glioblastoma. Neuro-Oncology (2024)

Multi-Platform Biomarkers of Response to an Immune Checkpoint Inhibitor in the Neoadjuvant I-Spy 2 Trial for Early-Stage Breast Cancer. Cell Reports Medicine (2024)

early-stage breast cancercancer biologymulti-platform biomarkerscancer researchmedicinebiomarkersimmune checkpoint inhibitorsbreast cancer

Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of Checkmate 627, an Adaptive Basket Design Clinical Trial. JCO oncology advances. (2024)

metastasisradiation oncologyrare cancerscancer immunotherapymetastatic malignanciesimmune checkpoint inhibitorsjama oncologycancer managementurologycancer treatmentcancer careoncologycheckmate 627

1
2
3
4
5
41
10 / page